Irvine CA, June 20th, 2023 – The 2022 Inflation Reduction Act (IRA) is poised to be the most revolutionary change to US drug pricing in decades, rapidly ascending as a top policy priority for manufacturers large and small. Innopiphany LLC., a life science consultancy, and expert network FirstThought cohosted this informational webinar on the IRA with former FDA commissioner and CMS administrator, Mark McClellan. This 1-hour virtual event addressed pressing questions regarding the role of various stakeholders, portfolio eligibility for negotiation, projections for the near and distant future, downstream consequences across the healthcare system, and steps manufacturers can take to prepare. This is a unique opportunity to hear Mark McClellan’s views on this important topic.
The remote webinar was held live on June 20, from 2:00 – 3:00pm ET.
Mark McClellan MD, Ph.D, served as the Food and Drug Administration commissioner of the FDA from 2002 to 2004, and the administrator of Centers of Medicare and Medicaid from 2004 to 2006, where he developed and implemented major reforms in health policy, including the Medicare prescription drug benefit and Medicare and Medicaid payment reforms. He has also previously served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and as Deputy Assistant Secretary for Economic Policy at the Department of the Treasury. He is currently the Director of Robert J. Margolis Center and a Professor of Business, Medicine, and Policy at the Duke-Margolis Center for Health Policy. Dr. McClellan also chairs the National Academy of Medicine’s Leadership Council for Value and Science-Driven Health Care, co-chairs the Guiding Committee of the Health Care Payment Learning and Action Network, and is a research associate at the National Bureau of Economic Research. He is a Senior Advisor on the faculty of the University of Texas Dell Medical School and independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ.
Lisa Kennedy, Ph.D, is Cofounder and Chief Economist of Innopiphany, LLC. specializing in strategy, new business model innovation, marketing, market access, macroeconomic health analysis and commercialization. Dr. Kennedy’s has previously served as GM for the Lewin Group Europe as well as Chief Economist and Global Head of Marketing Operations for GE Healthcare. Dr. Kennedy has several peer-reviewed articles and has spoken internationally to NASA, the NHS, the EU, SXSW, FutureMed and the White House Office of Science and Technology Policy (OSTP), HIMSS, among others. Dr. Kennedy has been quoted by the Wall Street Journal and National Public Radio on future healthcare trends in consumer health and received the 1994 Russel Trust Award and the Gray Prize for research that changed WHO practice in the treatment of tuberculosis in Addis Ababa, Ethiopia.